Capecitabine in Head and Neck Cancer Treatment
Capecitabine can be used in head and neck cancer treatment, but it is not a standard first-line option and should be reserved for specific clinical scenarios: recurrent/metastatic disease after platinum failure, as part of combination regimens in the palliative setting, or in cisplatin-ineligible patients where alternatives are limited.
Clinical Context and Evidence Base
The FDA-approved indications for capecitabine do not include head and neck cancer 1. However, clinical research demonstrates activity in this disease, particularly in specific contexts where standard options are exhausted or contraindicated.
Recurrent/Metastatic Disease Setting
For patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), capecitabine shows meaningful activity:
As monotherapy after platinum failure: A phase II study demonstrated a 24.2% overall response rate with capecitabine monotherapy in patients previously treated with platinum-based therapy, with median overall survival of 7.3 months and acceptable toxicity 2. This represents a reasonable palliative option when standard therapies have failed.
In combination regimens: The capecitabine-cisplatin (XP) combination achieved a 50% response rate in metastatic/recurrent HNSCC with median overall survival of 10.3 months 3. The capecitabine-lapatinib combination met its primary endpoint with median overall survival of 10.7 months, comparable to standard cisplatin/5-FU/cetuximab but with better tolerability 4.
Locally Advanced Disease
In the definitive treatment setting, capecitabine has been studied as a substitute for 5-FU in concurrent chemoradiation:
- Concurrent capecitabine-cisplatin with radiotherapy showed similar 3-year survival outcomes compared to cisplatin-5FU with radiotherapy, but with significantly better quality of life and similar toxicity profiles 5. This supports capecitabine as a reasonable alternative to infusional 5-FU when logistical considerations favor oral therapy.
Cisplatin-Ineligible Patients
Current guidelines acknowledge that many patients with locally advanced HNSCC are cisplatin-ineligible due to renal dysfunction, hearing loss, poor performance status, or advanced age 6. In this population with significant unmet need, treatment selection is often based on clinical judgment with few guideline-specified options 6. Capecitabine-based regimens represent a potential alternative, though prospective data in this specific population remain limited.
Important Caveats and Contraindications
Renal Function Requirements
Capecitabine is contraindicated in severe renal impairment (creatinine clearance <30 mL/min) and requires dose reduction in moderate impairment (CrCl 30-50 mL/min) due to 258% higher systemic exposure to toxic metabolites 1. This is critical since many cisplatin-ineligible patients have renal dysfunction.
Age Considerations
Patients ≥80 years experience significantly higher rates of grade 3-4 toxicity (62% vs lower rates in younger patients), particularly diarrhea (28.6%), hand-foot syndrome (14.3%), and nausea (14.3%) 1. Careful monitoring and dose adjustments are essential in elderly patients.
Key Toxicities to Monitor
- Diarrhea: Can be severe; median time to onset is 34 days. Interrupt therapy immediately for grade 2-4 diarrhea and use standard antidiarrheal agents 1
- Hand-foot syndrome: Occurs in 10-18% at grade 3 level across studies
- Warfarin interaction: Increases INR by 2.8-fold; requires intensive monitoring if concurrent anticoagulation is needed 1
Current Guideline Position
The most recent NCCN guidelines (2017,2025) emphasize immunotherapy agents (nivolumab, pembrolizumab) as category 1 recommendations for recurrent/metastatic disease after platinum failure 7, 8. Capecitabine is not specifically mentioned in major guidelines, reflecting its status as an off-label option supported by phase II data rather than definitive phase III trials.
Practical Algorithm for Use
Use capecitabine in head and neck cancer when:
Recurrent/metastatic disease after platinum-based therapy failure AND patient is not a candidate for immunotherapy (or has progressed on immunotherapy)
- Monotherapy: 1250 mg/m² twice daily, days 1-14 every 21 days
- Consider combination with cisplatin if platinum-rechallenge is appropriate
Locally advanced disease requiring concurrent chemoradiation when:
- Patient is cisplatin-ineligible due to renal dysfunction (but CrCl >30 mL/min)
- Logistical barriers prevent infusional 5-FU administration
- Use 750 mg/m² twice daily, days 1-14 with concurrent radiation
Adjuvant setting in nasopharyngeal carcinoma specifically (based on recent randomized data showing improved failure-free survival) 9
Do NOT use capecitabine when:
- CrCl <30 mL/min (absolute contraindication)
- Patient is eligible for standard cisplatin-based therapy or immunotherapy
- As first-line monotherapy in treatment-naive metastatic disease
The evidence supports capecitabine as a useful agent in the head and neck cancer armamentarium, but it remains a second-line or alternative option rather than standard first-line therapy in most scenarios.